AN2 Therapeutics
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results mere male placebo generally well tolerated no serious adverse events no severe aes no deaths linear and predictable results support further clinical development of in lung disease data from and other clinical studies combined into population model results used in combination with preclinical data to determine oral dosage for study phase pivotal trial once daily dose achieved high probability of target attainment for treatment of mac lung disease and was well tolerated an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
18 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results once daily dose achieved exposures suggesting high probability of target attainment for treatment of mac lung disease and was well tolerated through day so i generally an therapeutics | AN2 Therapeutics
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
GH Research
Investor Presentation
November 2023
phase single dose and phase safety | GH Research
Exscientia
Investor Presentation
November 2023
elucidate phase ongoing in advanced solid | Exscientia
Ocuphire Pharma
Investor Day
January 2022
phase clinical trials data supporting the zeta trial rat aches high levels in rat eye is orally | Ocuphire Pharma
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io